Rocket Pharmaceuticals, Inc. Common Stock (RCKT) Stock
NASDAQ · RCKT
2.54
Fundamentals
Market cap
$284.87M
Price / Earnings ratio
-17.1x
Price / Sales ratio
N/A
Price / Book ratio
0.8x
Return on assets
-60.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
NeutralRCKTSeptember 16, 2026
Zacks Investment ResearchNeutral
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
RCKT

Business Wire
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
NeutralRCKTSeptember 15, 2026
Business WireNeutral
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
RCKT

Zacks Investment Research
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
NeutralRCKTSeptember 9, 2026
Zacks Investment ResearchNeutral
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
RCKT

Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
NeutralRCKTSeptember 3, 2026
Business WireNeutral
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
RCKT
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
397M262M131M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-223.1M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
NeutralRCKTSeptember 16, 2026
Zacks Investment ResearchNeutral
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
RCKT

Business Wire
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
NeutralRCKTSeptember 15, 2026
Business WireNeutral
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
RCKT

Zacks Investment Research
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
NeutralRCKTSeptember 9, 2026
Zacks Investment ResearchNeutral
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
RCKT

Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
NeutralRCKTSeptember 3, 2026
Business WireNeutral
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
RCKT

Zacks Investment Research
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
NeutralRCKTAugust 11, 2026
Zacks Investment ResearchNeutral
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
RCKT

Business Wire
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
NeutralRCKTAugust 10, 2026
Business WireNeutral
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
RCKT

Business Wire
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
NeutralRCKTAugust 3, 2026
Business WireNeutral
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
RCKT

Business Wire
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
NeutralRCKTJune 12, 2026
Business WireNeutral
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
RCKT

Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
NeutralRCKTMay 28, 2026
Business WireNeutral
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
RCKT

Zacks Investment Research
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
NeutralRCKTMay 11, 2026
Zacks Investment ResearchNeutral
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
RCKT
About Rocket Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees202
CEODr. Gaurav D. Shah M.D.
IPO DateFeb 6, 2015
HeadquartersCranbury, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gaurav D. Shah M.D. | CEO & Director | 1975 |
| Mr. Martin Louis Wilson J.D. | Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | 1976 |
| Mr. Christopher Stevens | Chief Operating Officer | 1981 |
| Mr. Joseph Manhede | Principal Accounting Officer | 1978 |
| Dr. Jonathan Schwartz M.D. | Chief Science & Gene Therapy Officer | 1965 |
| Ms. Meg Dodge J.D., L.L.M. | Senior Vice President & Head of External Affairs | — |
| Ms. Sarbani Chaudhuri M.B.A. | Chief Commercial & Medical Affairs Officer | 1975 |
| Dr. Syed Ali-Aamir Rizvi M.D. | Chief Medical Officer | 1967 |
| Kevin Giordano | Director of Corporate Communications | — |
Fundamentals
Valuation
Market cap$284.87M
Price-to-sales ratioN/A
Price-to-book value0.80
Price-earnings ratio-17.10
Return on Equity-71.00%
Return on SalesN/A
Return on Assets-60.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.16
Income Statement
Average volume1,765,153
EBITDA$-197.31M
1 year high (52w)$5.45
1 year low (52w)$2.53
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$11.67
Est return
353.96%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.2 | -0.9 | -21.1 | -7.7 | ||||||||
| 2022 | -29.7 | +0.2 | -4.9 | -37.2 | +10.9 | +22.9 | +0.3 | +12.2 | +1.2 | +20.4 | -0.6 | +6.4 |
| 2023 | +13.4 | -12.6 | -15.4 | +0.2 | +14.3 | -5.1 | -9.6 | -12.4 | +28.1 | -6.9 | +22.8 | +28.0 |
| 2024 | -2.6 | +0.4 | -11.8 | -19.5 | -5.4 | -1.8 | +17.1 | -15.2 | +2.6 | -2.7 | -15.3 | -12.8 |
| 2025 | -15.6 | -10.5 | -24.1 | +31.3 | -68.1 | -11.6 | +17.8 | +9.7 | +0.6 | +19.3 | -3.9 | +11.1 |
| 2026 | +0.6 | +44.0 | -28.0 | -3.9 | -13.8 | +13.2 | -11.6 | +9.1 | -30.3 |



